Clinical and histochemical data have confirmed the efficacy of anti-PD-L1 monoclonal antibodies (mAbs) ICI as a neoadjuvant and adjuvant treatment for TNBC patients whose tumors and/or stromal cells (including tumor-infiltrating lymphocytes) express PD-L1. The gene discussed is CD274; the disease is neoplasm.